FDA 'recognises potential' of Redx drug to treat idiopathic pulmonary fibrosis
The US Food and Drug Administration (FDA) has given orphan drug designation (ODD) to Redx’s Zelasudil for the potential treatment of idiopathic pulmonary fibrosis (IPF).
Archives for August 21, 2023
Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation
Novartis’ board of directors has unanimously agreed to separate Sandoz as a 100 per cent spin-off with a $15 billion share buyback.